Home Featured Page 37

Featured

Latest

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Why Psychedelic Research is Booming: Current Trends and Hurdles

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and...

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Psychedelics on the Ballot 2024

Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Why Psychedelic Research is Booming: Current Trends and Hurdles

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and...

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Psychedelics on the Ballot 2024

Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY